Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Recruiting now · Not applicable
Conditions studied: Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancer, Hiatal Hernia With Gastroesophageal Reflux Disease, GIST - Gastrointestinal Stromal Tumor, Esophageal Cancer, Gallstones, Gastric Cancer
In brief
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic surgery. Recently, a new robotic surgical system (Sentire Robotic Surgical System) was introduced by researchers of The Chinese University of Hong Kong (CUHK). This new robotic surgical system aims to achieve similar outcomes and standards of robotic surgery performed using the dominating system but with a significantly lower cost. The technologic innovation and development of this new robotic system is made by the Cornerstone Robotics Limited, which is based in Hong Kong. In a pilot clinical study conducted at Prince of Wales Hospital involving 55 patients, the Sentire Robotic Surgical System had demonstrated high success rate with minimal complications in patients who underwent robotic colorectal, upper gastrointestinal, and urologic surgery. Researchers of CUHK would therefore like to conduct another prospective study to further evaluate the efficacy and safety of Sentire Surgical System C1000 in major gastrointestinal and urologic surgery with expanded indications. It is believed that the results of this study will provide data to support its use for wide range of procedures with minimal access trauma, for the benefit of patients. This system will also lead to a wider range of clinical application for minimally invasive surgery with a cost-effective model.
Key facts
- Study ID
- NCT06926374
- Run by
- Chinese University of Hong Kong
- People needed
- 90
- Starts
- 2025-03-25
- Expected to finish
- 2027-04-01
- Last updated by the study team
- 2025-04-16
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adenocarcinoma or large adenoma (not amenable to endoscopic removal) located at the colorectum (from the cecum to the anal verge) amenable to minimally invasive surgery
You may not qualify if…
- T4 tumor
- Recurrent tumor
- Extensive previous abdominal surgery precluding minimally invasive surgery
- Robotic Transanal Total Mesorectal Excision
- Inclusion Criteria:
- Mid/low rectal adenocarcinoma located <12 cm from the anal verge
- Exclusion Criteria:
- T4 tumor or involvement of circumferential resection margin even after neoadjuvant therapy
- Tumor requiring multivisceral resection
- Tumor requiring abdominoperineal resection; recurrent rectal tumor
- T1 tumor that can be treated by local excision
- Extensive previous abdominal surgery
- Robotic Rectopexy
- Inclusion Criteria:
- Clinically diagnosed with previously untreated and uncomplicated rectal prolapse or enterocele
- Exclusion Criteria:
- Extensive previous abdominal surgery precluding minimally invasive surgery
- Radical Prostatectomy
- Inclusion Criteria:
- Clinically diagnosed with nonmetastatic adenocarcinoma of prostate
- Exclusion Criteria:
- Previous history of prostate surgery (e.g., transurethral resection of prostate)
- Total or Partial Nephrectomy
- Inclusion Criteria:
- Clinically diagnosed with nonmetastatic kidney cancer
Where it is running
- Prince of Wales Hospital, The Chinese University of Hong Kong — Hong Kong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.